Geraldine O’Sullivan Coyne to lead early-stage clinical trials at Northwell’s START Center for Cancer Research

Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”

Five years ago, Tyler Jacks took on a new challenge, becoming president of Break Through Cancer, a foundation that has pledged to spend at least $500 million to support research projects across top tier cancer centers.

Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)

Amid deepening controversy, Vinay Prasad, FDA’s top clinician and scientist, and director of its Center for Biologics Evaluation and Research, will be leaving the agency.

March 13, 2026

Vol.52 No.10

By Claire Marie Porter

In Brief

Vivek Subbiah to lead Early Drug Development Program at Stanford Cancer Institute

Vivek Subbiah has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026.

March 13, 2026

Vol.52 No.10

In Brief

Lonny Yarmus named head of the Division of Subspecialty Medicine at MSK

Lonny Yarmus was appointed head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center. A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.

March 13, 2026

Vol.52 No.10

In Brief

Mass General Brigham receives $50M gift for gene and cell therapy research

Mass General Brigham has received a $50 million gift for gene and cell therapy research. The gift, made by anonymous donors, will advance clinical research by experts at Mass General Brigham Cancer Institute and throughout the system, to deliver treatments for patients with cancer and other diseases.

March 13, 2026

Vol.52 No.10